title: The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation following pars plana vitrectomy with long-acting gas tamponade.
abstract: OBJECTIVE
  To determine if topical aqueous suppressant therapy applied after pars plana vitrectomy (PPV) with gas tamponade successfully prevents postoperative elevation of intraocular pressure (IOP).
  
  
  METHODS
  A prospective, controlled study was performed on patients who met inclusion criteria and underwent PPV with gas tamponade (SF6 18%-20% or C3F8 12%-16%) over a 1-year period. Treatment eyes received topical aqueous suppressants at the end of surgery. Postoperative IOP checks were performed at 4 to 6 hours, 1 day, and 1 week.
  
  
  RESULTS
  Twenty-one control (C) and 20 treatment (T) eyes met the inclusion criteria. The IOP (in mm Hg) measured at 4 to 6 hours (23.05 [C], 14.73 [T] and 1 day (23.24 [C], 17.28 [T]) postoperatively showed a statistically significant difference between the groups (P = .0038) at 4 to 6 hours, and a trend toward significance (P = .057) at 1 day. Eleven control and 3 treatment eyes had an IOP spike above 25 mm Hg at 4 to 6 hours or 1 day postoperatively (P = .02), and 6 control and 1 treatment eye had a postoperative IOP above 30 mm Hg. A pressure rise above 40 mm Hg was seen in 2 control eyes and no treatment eyes.
  
  
  CONCLUSIONS
  Use of topical aqueous suppressants following PPV with long-acting gas tamponade is effective in preventing significant postoperative IOP elevation in a majority of cases.
authors.affiliation: Vitreoretinal Section of the Eye Institute, Medical College of Wisconsin, Milwaukee, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Mittra
authors.forename: J S
authors.initials: JS
authors.lastname: Pollack
authors.forename: S
authors.initials: S
authors.lastname: Dev
authors.forename: D P
authors.initials: DP
authors.lastname: Han
authors.forename: W F
authors.initials: WF
authors.lastname: Mieler
authors.forename: T B
authors.initials: TB
authors.lastname: Connor
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002924:Ciliary Body / Q000601:surgery*; D005740:Gases / Q000627:therapeutic use*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000517:prevention & control*; D009883:Ophthalmic Solutions; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D011446:Prospective Studies; D014821:Vitrectomy
chemical_list: D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D005740:Gases; D009883:Ophthalmic Solutions